

Advancing quality in IV and SubQ immunoglobulin therapy



Your partner in patient care

At Advanced Infusion Care, a division of AIS Healthcare, we apply a team approach to intravenous (IV) and subcutaneous (SubQ) immunoglobulin therapy patient care.

Collaboration between physicians and the nationally accredited AIC home infusion team ensures the consistent delivery of patient-specific, specialized in-home infusion services to patients across the country, helping to improve outcomes—and lives.

DOING MORE OF WHAT MATTERS

✓ A team approach to infusion care

Every AIC patient has 24/7 access to a dedicated team of experienced clinical and support staff, including Clinical Pharmacists, Infusion Nurse Specialists, Patient Care Managers and Intake Managers.

✓ Nationally recognized quality

Dually accredited by URAC and the Accreditation Commission for Health Care (ACHC), AIC is a member of the Immunoglobulin National Society (IgNS) and is regularly inspected by National and State Boards of Pharmacy.

✓ Billing and reimbursement made easy

We work with patients, our large network of payers and your office to secure needed authorizations and complete clinical paperwork as well as offer financial assistance to qualifying patients.

✓ Supply to meet your needs

We have long-term agreements with multiple suppliers to provide you and your patients with the right Ig infusion therapy.



How to refer patients to AIC

At AIC, we want to make patient onboarding as easy as possible. Use the documentation checklists and associated ICD-10 diagnosis codes below to send us the required patient information—we'll take it from there.

	agnosis codes below to seria as the required patien	e ii ii o i i i i a i o i i					
	TION NEEDED FOR PRIMARY IMMUNE	INFORMATION NEEDED FOR NEUROLOGY THERAPY REFERRALS:					
	CY DISEASE (PI) REFERRALS:						
✓ Patient demographic sheet✓ Copy of patient's insurance card		✓ Patient demographic sheet					
 Copy of patient's insurance card Prescription (including dose and frequency) 		Copy of patient's insurance card					
 Prescription (including dose and frequency) H&P (including supporting documentation 		Prescription (including dose and frequency)H&P					
of infection history)		✓ Recent BUN and creatinine results					
 Serum immunoglobulin levels (including IgA, IgG and IgM) 		✓ Nerve conduction velocity study					
✓ Ig1, Ig2, Ig3 and Ig4 subclass report (if available)		Lumbar puncture showing CSF protein levels					
✓ Recent BUN and creatinine results		✓ Diagnostic studies: nerve conduction studies/ EMG/ musels biopsy/ CK levels					
 ✓ Vaccine challenge test results and titer values ✓ Vascular Access Device (VAD) report, if applicable 		muscle biopsy/ CK levels Vascular Access Device (VAD) report, if applicable					
Vascaic	in necess bevice (vnb) report, ii applicable	▼ vasculal Access Device (vAD) report, il applicable					
Common ICD-10 codes for PI therapy:*		Common ICD-10 codes for neurology therapy:*					
ICD-10 CODE	EDESCRIPTION	ICD-10 COD	E DESCRIPTION				
D80.0 [†]	Hereditary hypogammaglobulinemia	D89.8	Disorder involving the immune mechanism, unspecified				
D80.1	Nonfamilial hypogammaglobulinemia	G25.82	Stiff-man syndrome				
D80.2 [‡]	Selective deficiency of IgA	G35	Multiple sclerosis (RRMS)				
D80.3 [‡]	Selective deficiency of IgG subclasses	G60.9	Hereditary and idiopathic neuropathy, unspecified				
D80.5 [‡]	Immunodeficiency with increased IgM	G61	Inflammatory polyneuropathy				
D80.6‡	Antibody deficiency with near-normal immunoglobulins	G61.0	Guillain-Barre syndrome				
D81.0 [†]	SCID with reticular dysgenesis	G61.81	Chronic inflammatory demyelinating polyneuritis				
D81.1 [†]	SCID with low T- and B-cell numbers	G61.82	Multifocal motor neuropathy				
D81.2 [†]	SCID with low or normal B-cell numbers	G61.9	Inflammatory polyneuropathy, unspecified				
D81.6 [†]	Major histocompatibility complex class I deficiency	G70.0	Myasthenia gravis and other myoneural disorders				
D81.7 [†]	Major histocompatibility complex class II deficiency	G70.01	Myasthenia gravis with (acute) exacerbation				
D81.89 [†]	Other combined immunodeficiencies	G70.80	Lambert-Eaton syndrome, unspecified				
D81.9 [†]	Combined immunodeficiency, unspecified	G72.41	Inclusion body myositis				
D82.0 [†]	Wiskott-Aldrich syndrome	G72.49	Other inflammatory and immune myopathies				
D82.9	Immunodeficiency associated with major defect, unspecified	G73.1	Lambert-Eaton syndrome in neoplastic disease				
D83.0 [†]	CVID with predominant abnormalities of B-cell numbers and function	M34.82	Scleroderma				
D83.1‡	CVID with predominant immunoregulatory T-cell disorders	M32.19	Systemic lupus erythematosus				
D83.2 [†]	CVID with autoantibodies to B- or T-cells	M33.1	Dermatomyositis				
D83.8 [†]	Other common variable immunodeficiencies	M33.2	Polymyositis				
D83.9 [†]	CVID, unspecified						


^{*}These ICD-10 codes fall under the disease states listed in Jolles, S et al. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1-11. doi:10.1111/j.1365-2249.2005.02834.
†These ICD-10 codes reflect diagnoses that are payable for IG home infusion under Medicare Part B as published in IDF: SCID Compass. More PI diagnoses covered for home Ig replacement therapy under Medicare Part B. July 2019. https://primaryimmune.org/scid-compass/news/more-pi-diagnoses-covered-home-ig-replacement-therapy-under-medicare-part-b.
‡These ICD-10 codes were added per CMS guidelines, effective August 2019, as published in IDF: SCID Compass. See reference directly above.

Discover our selection of immunoglobulin products

Learn more about the IV and SubQ immunoglobulin therapy products that we offer. Want selection or dosing guidance? Our clinical pharmacists are ready to help you pick the products that meet the health conditions and restrictions of your patients.

	ASCENIV"	BIVIGAM°	CUTAQUIG*		IMAGARD IQUID®	GAMMAGARD° S/D	GAMMAKED ** Kedrion	
Manufacturer	ADMA Biologics Inc.	ADMA Biologics	Octapharma	Takeda		Takeda		
Indications	PI	Pl	PI	IV: PI, MMN	SubQ: PI	PI, ITP, B-cell CLL, Kawasaki disease	IV: PI, ITP, CIDP	SubQ: PI
Form	Liquid	Liquid	Liquid	Liquid		Lyophilized	Liquid	1
Shelf life and storage requirements	Refrigerate at 2–8°C (36–46°F). Do not freeze or heat. Do not use after expiration date.	Stored until expiration date on vial packaging at 2–8°C (36–46°F)	24 months (refrigerated) 6 months (room temperature storage not exceeding 77°F)	36 months (refrigerated 24 months (room temp not exceedi	erature storage	24 months (room temperature storage)	36 months	
Reconstitution time	None (liquid solution)	None (liquid solution)	None (liquid solution)	None (liquid solution)		n/a	None (liquid solution)	
Available concentration	10%	10%	16.5%	10%		5%	10%	
Maximum recommended infusion rate	Up to 0.08 mL/kg per minute	Up to 6 mL/kg/ minute	Up to 100 mL/ hour at all sites combined	5 mL/kg per hour	≥40 kg BW: 30 mL/site at 20–30 mL/ hour per site ≤40 kg BW: 20 mL/site at 15–20 mL/hour per site	4 mL/kg per hour	4.8 mL/ kg per hour	20 mL/ per hour
Time to infuse 35 g	Varies based on volume and tolerability	Varies based on volume and tolerability	Varies based on patient tolerability	Varies based on patient tolerability		Varies based on patient tolerability	Varies based on administration method	
Sugar content	Contains no sucrose	Contains no sucrose/glucose/ maltose	79 mg/mL (maltose)	No added sugars		20 mg/mL (glucose)	None	
Sodium content	0.100-0.140 M (sodium chloride)	0.100-0.140 M (sodium chloride)	≤30 mmol/L	No added sodium		8.5 mg/mL (sodium chloride)	Trace amounts	
Osmolarity/ osmolality	240-310 mOsm/kg	454–472 mOsm/kg	310-380 mOsm/kg	240-300 mOsm/kg		636 mOsm/kg	258 mOsm/kg	
рН	4.0-4.6	4.0-4.6	5.0-5.5	4.6-5.1		6.8 ± 0.4	4.0-4.5	
IgA content	≤ 200 μg/mL	Contains trace amounts of IgA	≤0.6 mg/mL	37 μg/mL		<1µg/mL	46 μg/mL	
Approved method of administration	IV	IV	SubQ	IV	SubQ	IV	IV	SubQ

GAMMAPLEX*		GAMUNEX*-C		HIZENTRA®	HYQVIA*	ОСТА	GAM*	PANZYGA*	PRIVIGEN®	XEMBIFY*
Bio Products Laboratory		Grifols		CSL Behring	Takeda	Octaph	narma	Pfizer	CSL Behring	Grifols
PI,ITP		IV: PI, ITP, CIDP	SubQ: Pl	PI, CIDP	PI	5%: PI 10%: ITP		PI,ITP	PI, ITP	PI
Liquid		Liquid		Liquid	Liquid	Liquid		Liquid	Liquid	Liquid
36 months (room temperature storage)		36 months		30 months (room temperature storage)	36 months (refrigerated at 36–46°F) 3 months (room temperature storage not exceeding 77°F)	24 months		24 months (refrigerated up to 46°F) 9 months (room temperature storage not exceeding 77°F)	36 months (room temperature storage)	36 months (refrigerated at 36–46°F) 6 months (room temperature storage not exceeding 77°F)
None (liquid solution)		None (liquid solu	ution)	None (liquid solution)	None (liquid solution)	None (liquid s	solution)	None (liquid solution)	None (liquid solution)	None (liquid solution)
5%	10%	10%		20%	10%	5%	10%	10%	10%	20%
4.8 mL/kg per hour		4.8 mL/ kg per hour	20 mL/ per hour	Up to 25 mL/ hour per site (50 mL/hour for all sites combined)	<40 kg BW: maximum of 16 mL/site >40 kg BW: maximum of 16 mL/site	≤4.2 mL/kg perhour		0.01 mL/kg per minute	4.8 mL/kg per hour	25 mL/hour per site
2 hrs, 40 min for a 70 kg person, if infused according to PI	1 hr, 53 min for a 70 kg person, if infused according to PI	Varies bas administra method		Varies based on volume and tolerability	Varies based on patient tolerability	2 hours, 30 minutes		Varies based on patient tolerability	Varies based on patient tolerability	Varies based on volume and tolerability
5% D-sorbitol (polyol)				None	No added sugars	10 mg/mL (maltose)		None	None	None
30-50 mmol/L			ounts	Trace amounts (≤10 mmol/L)	8.5 mg/mL in HYQVIA (none in immunoglobulin)	≤30 mmol/L		Trace amounts	Trace amounts	Trace amounts
460 - 500 ~280 mOsmol/kg mOsm/kg		258 mOsm/kg		380 mOsm/kg	240-300 mOsm/kg	310-380 mOsm/kg		240-310 mOsm/kg	Isotonic (380 mOsmol/kg)	280-404 mOsm/kg
4.6-5.1 4.9-5.2		4.0-4.5		4.6-5.2	4.6-5.1	5.1–6.0		4.5–5.0	4.8	4.1–4.8
<4 mcg/mL <20 mcg/mL (average) (specification value)		46 μg/mL		≤50 mcg/mL	37 μg/mL	100 μg/mL		100 µg/mL (average)	≤25 mcg/mL	IgA <0.07 mg/ mL
IV		IV	SubQ	SubQ	SubQ	DQ IV		IV	IV	SubQ



It's easy to get started

At AIC, we want to be your partner in patient care. To get your patients started on infusion therapy, simply complete a referral form—forms for both IV and SubQ therapies are on our website (advancedinfusioncare. com). Submit the referral form along with the patient's Vascular Access Device (VAD) report, if applicable. Once the referral is evaluated by a clinical review specialist, an AIC representative will be in touch.

To learn more about our in-home infusion services or the products we offer, please contact us.